Baxter (NYSE:BAX) said today it is collaborating with Chicago-based healthcare incubator Matter to advance new, innovative products and technologies focused on patient-driven innovation.
Through the collaborative agreement, Deerfield, Ill.-based Baxter will provide resources and expertise to entrepreneurs in the incubator looking to address unmet clinical needs.
“Baxter is one of the world’s great healthcare companies, with products in hospitals around the globe. Matter is thrilled to partner with Baxter to create collaborations with entrepreneurs that will help develop next-generation products and solutions to improve health and lives,” Matter CEO Steven Collens said in a press release.
Baxter will also gain access to Matter’s program suite, including introductions to member companies, proprietary access to technologies developed through partners and opportunities to explore the incubators entrepreneurial network for other business objectives.
“Our work with Matter will help Baxter provide meaningful support for healthcare innovation in Chicago. Our partnership with Matter extends Baxter’s efforts to access new sources of innovation. Importantly, we can help advance new ideas that have the potential to greatly improve healthcare here and around the world,” Baxter strategy VP David Roman said in a prepared statement.
Last month, Baxter said it closed its $625 million acquisition of Claris Lifesciences‘ (BOM:533288) injectable drug biz.